SLC1A5 and prostate carcinoma: Taken together, pharmacological inhibition of ASCT2 provoked cell line‐specific effects on the flux of glutamine as a fuel source, yet ultimately led to reduced OCR and cellular lipid levels in both prostate cancer cell lines.